At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-β or No Disease Modifying Therapy
In Brief
A Phase 3 clinical trial evaluating Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, and 1 other intervention for Multiple Sclerosis and Multiple Sclerosis, Relapsing-Remitting. Completed, enrolled 63 participants across 33 sites in 2 countries.
Detailed Summary
This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no disease modifying therapies (DMTs). The data of this study will support the labels for ozanimod in multiple sclerosis (MS) because the effect of ozanimod on the vaccination response of MS participants is of interest to participants and prescribers.
Study Details
Timeline
Interventions
Tdap
PPSV23
Seasonal influenza vaccine